It's in every luxury skincare line. It's also a serious research peptide with 50 years of published data. Here's what it actually does โ and why injectable and topical aren't the same thing.
Research context only. All content is educational based on published research. Not medical advice.
GHK-Cu is a naturally occurring copper peptide โ a tripeptide (glycyl-L-histidyl-L-lysine) bound to a copper ion. It was first isolated from human plasma in 1973 by Dr. Loren Pickart, who discovered it was responsible for stimulating liver tissue regeneration. What started as a wound healing compound became one of the most studied peptides in dermatology, anti-aging, and systemic tissue repair.
Your body naturally produces GHK-Cu, and levels decline significantly with age โ from roughly 200 ng/mL at age 20 to around 80 ng/mL by age 60. This decline correlates with reduced wound healing capacity, skin thinning, and increased inflammatory tone. Supplementing GHK-Cu replenishes what the body makes less of as it ages.
The one-line version: GHK-Cu is a copper-carrying tripeptide your body already makes that repairs tissue, rebuilds collagen, reduces inflammation, and resets gene expression toward a younger pattern. It works topically on skin and systemically when injected โ with meaningfully different outcomes for each route.
GHK-Cu's most remarkable documented effect is its influence on gene expression. Research by Pickart and Margolina identified that GHK-Cu upregulates ~31% of genes associated with tissue repair and downregulates ~16% of genes associated with inflammation and cancer pathways. It essentially shifts cellular behavior toward a younger, more repair-oriented state.
GHK-Cu stimulates fibroblasts to produce more collagen, elastin, and glycosaminoglycans โ the structural proteins that give skin its firmness and elasticity. This is the mechanism behind its well-documented skin-tightening effects in topical studies.
GHK-Cu attracts immune cells (macrophages, mast cells) to wound sites, stimulates keratinocyte migration for wound closure, and promotes angiogenesis โ the formation of new blood vessels that supply healing tissue.
GHK-Cu suppresses inflammatory cytokines including TGF-ฮฒ1 (a key driver of fibrosis and scarring), TNF-ฮฑ, and IL-6. The copper ion itself is an essential cofactor for superoxide dismutase โ a primary antioxidant enzyme โ contributing to cellular oxidative stress protection.
The gene expression finding is significant: Most compounds affect one or a few pathways. GHK-Cu's influence on hundreds of genes simultaneously โ identified through transcriptomic analysis โ suggests it acts as a biological signaling molecule that coordinates tissue maintenance rather than simply triggering a single downstream effect.
GHK-Cu's topical evidence base is unusually strong for a research peptide. Multiple randomized controlled trials in humans have demonstrated improvements in skin density, fine lines, skin laxity, and wound healing speed. The dermatology literature on copper peptides is more developed than almost any other peptide category.
Animal studies show systemic effects from injectable GHK-Cu: accelerated wound healing, lung tissue repair, antifibrotic effects in liver and kidney models, and neuroprotective effects. The systemic injectable use draws on this animal data plus the biological rationale from topical human trials.
Topical vs injectable evidence split: The human RCT data is overwhelmingly topical. Injectable GHK-Cu has a strong mechanistic and animal model basis โ but the human trial data for systemic injection is thinner than for topical application. This is a real asymmetry worth understanding before choosing your research protocol.
Stacking context: GHK-Cu is a natural component of the KLOW and Glow Blend stacks on S1 Research โ combined with BPC-157, TB-500, and KPV for comprehensive tissue repair. It's also frequently researched alongside BPC-157 for wound and connective tissue healing, where the mechanisms complement each other.
GHK-Cu has an excellent safety profile. It's a naturally occurring human peptide, and the decades of topical use in cosmetics have produced no significant safety signals. For injectable use:
No serious adverse events have been reported in the published literature for GHK-Cu at research doses. The compound's long history in cosmetics and the research literature both support a favorable safety profile.
They're the same molecule but very different bioavailability. Topical copper peptides primarily affect the skin layers they penetrate โ which is meaningful for skin aging but limited in scope. Injectable GHK-Cu reaches systemic circulation, affecting tissue throughout the body. The mechanisms are the same; the reach is completely different.
GHK-Cu has more peer-reviewed research behind it than most injectable peptides. The topical/cosmetic familiarity makes people dismiss it, but the published literature on its gene expression effects and wound healing mechanisms is scientifically substantial.
GHK-Cu works as a signaling molecule โ it doesn't function by flooding tissues with copper. The peptide-copper complex is the active form, and research doses are calibrated to the signaling concentration, not to copper supplementation levels. Megadosing doesn't improve outcomes and increases the risk of copper imbalance.
COA-verified vendor pricing with promo codes and reconstitution guide.
View Pricing โ Dosage Calculator